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Background WHO recommends high-dose Vitamin A supplementation (VAS) at
vaccination contacts after 6 months of age. It has not been studied
whether the effect of VAS on mortality depends on the type of
vaccine. We have hypothesized that VAS administered with measles
vaccine (MV) is more beneficial than VAS with diphtheria–tetanus–
pertussis (DTP) vaccine. We assessed the effect of VAS administered
with different vaccines during national immunization days (NIDs).
Methods In 2003, VAS was distributed during NIDs in Guinea-Bissau.
Children 6 months or older were given VAS, and if they were miss-
ing vaccines, these were often given as well. We compared survival
between children who had received VAS alone, VAS with DTP or
DTPþMV, or VAS with MV. We also compared the survival between
participants and non-participants. We followed 6- to 17-month old
children until 18 months of age and analysed survival in Cox models.
Results Twenty of 982 VAS-recipients died during follow-up. Themortality rate
ratio (MRR) for VAS with DTPþMV or VAS with DTP was 3.43 (1.36–
8.61)comparedwithVASonly.Therewerenodeathsamongthosewho
received VAS with MV alone (P¼0.0005 for homogeneity of VAS
effects).ChildrenwhoreceivedVASwithDTPhadhighermortalitythan
non-participants who did not receive VAS [MRR¼3.04 (1.31–7.07)].
Conclusion The study design does not allow for definite conclusions. However,
the results are compatible with our a priori hypothesis that VAS is
more beneficial when given with MV and potentially harmful when
given with DTP. Randomized trials testing the impact on mortality
of the current WHO policy seem warranted.
Keywords Vitamin A, diphtheria–tetanus–pertussis vaccine, measles vaccine,
child mortality, low income populations
Introduction
The WHO recommends high-dose vitamin A supple-
mentation (VAS) at vaccination contacts after 6
months of age.
1 The recommendation is based on
several large intervention trials showing VAS to be
associated with a 23–30% reduction in overall
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304mortality in children aged 6 months to 5 years
of age.
2,3 However, none of those studies adminis-
tered VAS simultaneously with vaccines, and hence,
it is unknown whether the current WHO policy
of providing VAS in combination with vaccines
has a similar mortality-reducing effect as VAS
administered alone. In particular, it has not been
studied whether VAS is equally beneficial when
administered with measles vaccines (MV) or with
other vaccines such as diphtheria–tetanus–pertussis
(DTP) vaccine.
We have previously hypothesized that VAS and DTP
vaccine may interact negatively.
4 The hypothesis was,
among others, based on the observation that the
effect of VAS given between 1 and 5 months of age,
i.e. the time window in which DTP vaccine is
administered, is significantly different from the
beneficial effect of VAS given at birth or after 6
months of age.
4 To date, no study has reported a
beneficial effect of VAS between 1 and 5 months of
age (Table 1).
In Guinea-Bissau, VAS has been distributed in
connection with yearly national immunization days
(NIDs). Mostly, VAS has been given with oral polio
vaccine (OPV). However, the NIDs in 2003 were
different. Children aged 6–60 months were given VAS,
and if vaccines were missing, these were administered
at the same time. Thus, children received either VAS
alone, VAS with DTP, VAS with MV or VAS with
DTPþMV.
In the study area of the Bandim Health Project (BHP),
study assistants accompanied the health workers and
registered all children and their treatment during the
NIDs. All study area children were followed routinely
through the BHP’s demographic surveillance system.
We took the opportunity to study the potential
differential effects of VAS on mortality when adminis-
tered with different vaccines. We focused our study on
6- to 17-month old children, since they were too young
to have received VAS in previous campaigns. We
followed up the children till the age of 18 months,
since many children receive DTP booster vaccine at the
age of 18 months or were enrolled in a BCG revaccina-
tion study at the age of 19 months.
Methods
Setting
The BHP has a demographic surveillance system in six
suburban districts of the capital of Guinea-Bissau and
covers approximately 90000 inhabitants. Until 3 years
of age, all children are visited every third month to
obtain information on vital status, hospitalizations,
vaccinations, measles infections, etc. Mid-upper-arm
circumference (MUAC) is measured. Information on
vaccinations and survival is also registered by the BHP
at the three health centres in the study area and at
the only paediatric ward in the country.
Table 1 The effect on overall mortality of vitamin A supplementation given between 1 and 5 months of age
Author, country and year (ref)
No. of
children
Vitamin A supplementation
dosing regimen
Overall effect of vitamin A vs
placebo/control [RR (95% CI)]
In pre-DTP era
Patwardhan et al.
5 (Jordan) 180 300000IU 0.50 (0.13–1.94)
Single dose, not given with DTP vaccine
Daulaire et al.
6 (Nepal) 1058 50000IU 0.99 (0.41–2.41)
West et al.
7 (Nepal) 10297
a 100000IU 4-monthly 1.12 (0.85–1.47)
25000IU given with the three DTP vaccines
Rahman et al.
8 (Bangladesh) 199 25000IU 3 with DTP 0.97 (0.29–3.25)
WHO
9 (Ghana, India and Peru) 9424 25000IU 3 with DTP
c 0.96 (0.73–1.27)
b
Newton et al.
10 (Ghana) 1034 25000IU 3 with DTP
d 2.38 (0.62–9.15)
50000IU given with the three DTP vaccines
Mahalanabis et al.
11
(Bangladesh)
200 50000IU 3 with DTP Any DTP: 1.06 (0.52–2.18)/
DTP2þ3: 3.54 (0.76–16.5)
e
Newton et al.
12 (Ghana) 1077 50000IU 3 with DTP 3.71 (0.42–33.06)
a1621 children enrolled at 0 months of age excluded, mortality rate ratio calculated based on Table 2.
7
bAt 9 months of age. The survival curves indicate increased mortality in vitamin A group up to 6 months of age.
9
cThe mothers of children in the vitamin A group had received a post-partum vitamin A supplement.
dHalf of the mothers in each treatment group had received a post-partum vitamin A supplement as well in a two-by-two factorial
design.
eFirst dose of vitamin A and DTP was given to children with diarrhoea. VAS appeared to be beneficial when given to children with
diarrhoea [0.58 (0.22–1.51)]. The estimates presented are of the effect of VAS overall and the effect of VAS when given to children
with DTP2 and DTP3 (without diarrhoea).
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are to receive BCG and OPV at birth, three DTP/OPV
vaccines at 6, 10 and 14 weeks of age and MV at
9 months of age. The WHO recommendations for VAS
after 6 months of age are not implemented in Guinea-
Bissau; instead, VAS is being delivered during NIDs,
usually in combination with OPV.
Procedures
The Ministry of Health in Guinea-Bissau has
organized yearly immunization days since 2001. The
NIDs in November 2003 differed from previous and
later campaigns offering VAS and OPV. In 2003,
all children aged 6–60 months were offered VAS.
Additionally, infants <12 months of age should
receive missing vaccines, since they are the target
group for the vaccination programme. In contrast to
the previous NIDs, the NIDs in 2003 were not
organized as door-to-door visits; instead, all children
were called to fixed vaccination posts. These posts
were staffed by three to four health workers. The
mothers were told to bring the vaccination card. In
the study area of the BHP, trained fieldworkers were
present at all posts with a list of all children in the
area. The field worker compared the information on
the list with the vaccination card of the child. Missing
information was noted on the list as well as the
information regarding the vaccines the child received
that day. If a mother had not brought a vaccination
card, the child was vaccinated if the child was
missing one or more vaccines on the list and as
reported by the mother.
Children aged 6–60 months were eligible for VAS if
they had not received VAS within the last month and
were not enrolled in an ongoing trial of VAS at
birth.
13 Children below 12 months of age received
100000 IU VAS as recommended by the WHO.
Provided maternal consent was given, children aged
12 months and older were randomized to 200000 IU
of VAS as recommended by WHO or half of this dose.
VAS was distributed orally from gelatine capsules
containing retinyl palmitate (International Dispensary
Association, The Netherlands).
Children missing one or more DTP vaccines were
offered DTP vaccine together with VAS. Children who
were above 9 months of age and missing MV were
offered a MV together with VAS. Some children above
9 months of age missed DTP as well as MV and were
given both.
The NIDs were not well organized. First, the public
information level was low and many mothers never
heard of the campaign, and therefore did not attend.
Second, apparently there was confusion among the
health workers as to who should receive missing
vaccines. Some teams apparently had misunderstood
and provided missing vaccines also to children above
12 months of age. Some teams ran out of vaccines
or syringes. Some calculated the age wrongly. As a
result, some children who were missing one or more
vaccines according to the schedule did not receive any
vaccines.
Follow-up
We followed all study area children for mortality until
18 months of age, at which age most received booster
doses of DTP and OPV and were enrolled in a study
of revaccination with BCG.
14 Information on survival
and vaccination status was obtained from the
BHP registration system. If a child died, a simple
interview was performed to establish the cause of
death. Children in the BHP registration system, but
not seen during the NIDs, were visited by a field
assistant during the months after the NIDs to
ascertain the reason for non-participation.
Nutritional status
We utilized the information on MUAC from the
routine visits every 3 months to assess the nutritional
status in the subgroup of children who had had their
MUAC measured within 3 months before the NIDs.
Statistical analyses
Mortality rates (MR) were presented per 1000 person-
years of risk (pyrs). Survival was assessed in Cox
proportional hazards models with age as the under-
lying time variable. Thus, age was inherently con-
trolled for in the model. Effects are shown as MR
ratios (MRR) with 95% CI. Children were censored
at 18 months of age or if they moved. In a second
analysis, we censored children when they got a
subsequent vaccine. Three children who died due to
an accident were censored in the analysis at the time
of death. Eight children who developed a measles
rash within the 2 weeks after supplementation were
excluded, since they were considered infected prior to
the NIDs. Among them, a recipient of VASþMV died
12 days after supplementation.
All comparisons between recipients of VASþMV vs
other groups were done using a stratified log-rank
test, since there were no deaths in that group.
All analyses were adjusted for suburb (Bandim,
Belem/Mindara or Cuntum) and maternal schooling
(none, any or unknown). The comparisons of
participants and non-participants were furthermore
adjusted for ethnicity (Pepel, Fula and others).
We tested the size of the estimates with and without
control for nutritional status in the subgroup that had
MUAC measured within 3 months prior to the NIDs.
This was done by adding to the model MUAC and age
at measurement of MUAC as continuous variables.
Children above 12 months of age were randomized
to full or half the WHO recommended VAS dose. The
trial is registered with clinicaltrials.gov, number
NCT00168623. We have previously shown that half
the recommended dose was more beneficial for
girls.
15 The results of the randomized trial will be
presented separately. This observational subgroup
306 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYstudy of children between 6 and 17 months of age did
not have power to investigate the association between
dose of VAS and mortality. Among the 648 children
who were above 12 months of age, eight deaths
occurred, five in the group receiving the low dose
(three boys and two girls) and three in the group
receiving the high dose (two boys and one girl). We
did not consider dose further in the analyses.
Results
Figure 1 shows the flow chart of infants enrolled in
the study. Table 2 shows the baseline characteristics
by treatment group. Treatment was associated with
suburb, age of the child and maternal education, and
with MUAC. We adjusted all subsequent analyses for
age, suburb and maternal education. The analyses
including all children were furthermore adjusted for
sex. In the subgroup of children from whom a valid
MUAC was available, we adjusted the estimates
for MUAC.
The effect on mortality of VAS according
to vaccination
Twenty (MR¼50/1000 pyrs) of the 982 children died
during follow-up. Compared with children receiving
VAS alone, the MRR for children receiving VAS with
DTPþMV was 3.60 (95% CI¼1.22–11); for VAS with
DTP alone, it was 3.19 (0.89–11). The MRR for VAS
with MV alone was 0. Since the effect of VAS given
with DTP was similar to that of VAS given with
DTPþMV, we combined the two groups to gain
power to study the effect of VAS given with different
vaccines. As seen in Table 3, there was a negative
effect of receiving VAS with any DTP in contrast to
the effect of receiving VAS with MV alone.
The results were unchanged if we included only the
835 (85%) children who had their vaccination card
seen at inclusion; VAS with any DTP was associated
with a MRR of 4.10 (1.48–11) compared with VAS
alone (P¼0.0003 for homogeneity of VAS with DTP
vs VAS with MV).
Three deaths occurred after a subsequent vaccine
had been received. When censoring on the date of the
next vaccination, the estimate for VAS with any DTP
vs VAS alone became 2.82 (1.04–7.66) (P¼0.0003 for
homogeneity of VAS with DTP vs VAS with MV).
MUAC had been measured within 3 months in 657
(67%) of the children. The proportion of children who
had had their MUAC measured was comparable in
the different treatment groups (P¼0.21). Among
children who had had their MUAC measured, 12
children died. Compared with receiving VAS alone,
the estimate of children receiving VAS with DTPþ
MV was 2.95 (0.57–15); for VAS with DTP alone it
was 2.82 (0.56–14), and for VAS with any DTP it was
2.88 (0.83–10). MUAC tended to be lower among
those who received VAS with DTPþMV compared
with children who received VAS only (P¼0.07).
However, control for MUAC did not change the
estimates much, though the confidence intervals
were naturally wider; VAS with DTPþMV: 2.82
(0.53–15); VAS with DTP alone: 2.45 (0.46–13); VAS
with any DTP: 2.62 (0.72–9.50).
The effect of DTP without VAS
A total of 532 infants came to the health post but did
not receive VAS, because they took part in a VAS-at-
birth trial (Figure 1). They received vaccines if
*Three children received only OPV, none died.
Between 6 and 17 month old and
living in study area: 2416
Not attending NIDs: 896 (441 travelled/
absent (13 died); 13 erroneously
thought <6 mo; 17 received vitamin A else-
where; 49 ill (2 died); 6 did not want to par-
ticipate; 276 had not heard of NIDs or came
too late (4 died); 94 not found to establish 
reason for non-participation (1 died)).
DTP
(48)
No vaccine
(730)
MV/OPV*
(116)
DTP+MV
(88)
12 died (6M/6F)
MR=42
3 died (2M/1F)
MR=134
5 died (3M/2F)
MR=143 
0 died
20 died (9M/11F)
MR=50
6 developed measles
within the first 2 weeks
Did not receive VAS: 532 
(In another vitamin A study.
Only received vaccines if
missing vaccines).
No vaccines: 419 (9 died, MR=30).
DTP/DTP+MV: 51 (2 died, MR=55)
MV: 61 (0 died)
Attending NIDs: 1520
Received VAS: 988
1 developed measles
within the first 2 weeks
1 developed measles
within the first 2 weeks
1 died in accident
2 died in accident 
Figure 1 Flow diagram. Children aged 6–17 months during national immunization days (Guinea-Bissau, 2003–2004)
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died (MR¼29/1000 pyrs); among 51 DTP recipients,
two children died (MR¼55/1000 pyrs).
Comparison of VAS recipients and
non-participants
Seventeen children received VAS elsewhere. Among
the remaining 878 children who did not participate in
the NIDs, 20 (MR¼50/1000 pyrs) died. This resulted
in a MRR for participants vs non-participants of 1.11
(0.59–2.08) controlled for suburb, maternal education,
sex and ethnicity. There was no difference in MUAC
between participants and non-participants (P¼0.51).
Excluding children who were away/travelling
(n¼441) or too ill to participate (n¼48) among
the non-participants, the MRR for participants vs
non-participants was 2.05 (0.76–5.54). Comparing the
VAS plus any DTP group with the non-participants,
the MRR was 3.04 (1.31–7.07). There were no
differences between the two sexes.
Discussion
As VAS is an important immunomodulator, several
groups have studied whether simultaneous adminis-
tration of VAS influences the immune response to
specific vaccines. Apart from one study, no evidence
was found for a negative effect of VAS on the
immune response to OPV and MV,
16 and VAS may
even be associated with increased antibody responses
to Hepatitis B vaccine
12 and to MV, particularly in
boys.
17 No study, however, has addressed the effect
Table 2 Baseline characteristics of children receiving VAS alone or with missing vaccines and of non-participants
(Guinea-Bissau, 2003)
Participants Non-participants
VAS alone VASþDTP VASþMVþDTP VASþMV No VAS
N 730 48 88 116 531 895
Median age, months
a
(10–90 percentiles)
13.5 (8.0–17.2) 12.6 (7.3–17.0) 12.9 (8.9–17.0) 10.5 (8.7–16.3) 8.9 (6.6–11.5) 11.3 (7.5–16.7)
Sex
Boys 368 (50%) 23 (48%) 52 (59%) 59 (51%) 277 (52%) 448 (50%)
Girls 362 (50%) 25 (52%) 36 (41%) 57 (49%) 254 (48%) 447 (50%)
Suburb
b
Bandim 283 (39%) 21 (44%) 44 (50%) 37 (32%) 306 (58%) 398 (44%)
Belem/Mindara 172 (24%) 5 (10%) 5 (6%) 10 (9%) 102 (19%) 151 (17%)
Cuntum 275 (38%) 22 (46%) 39 (44%) 69 (59%) 123 (23%) 346 (39%)
Ethnicity
c
Pepels 220 (30%) 15 (31%) 35 (40%) 32 (28%) 164 (31%) 258 (29%)
Fulas 81 (11%) 8 (17%) 10 (11%) 15 (13%) 59 (11%) 163 (18%)
Others 429 (59%) 25 (52%) 43 (49%) 69 (59%) 308 (58%) 474 (53%)
Maternal schooling
d
No 193 (26%) 16 (33%) 45 (51%) 41 (35%) 101 (19%) 275 (31%)
Yes 446 (61%) 26 (54%) 32 (36%) 67 (58%) 354 (67%) 500 (56%)
Unknown 91 (12%) 6 (13%) 11 (13%) 8 (7%) 76 (14%) 120 (13%)
Mean mid-upper-arm-
circumference (SD)
e 145.6 (12.4) 142.7 (10.8) 142.3 (12.6) 143.5 (12.5) 144.1 (12.3) 143.6 (11.9)
(percentage with valid
measurement)
(69%) (60%) (60%) (63%) (74%) (48%)
aSignificant differences in age between VAS alone and VASþDTP (t-test¼0.01) and VASþMV (<0.0001) and between VASþMV
and VASþDTPþMV (P¼0.003). Non-participants younger than participants (P<0.0001). No-VAS recipients younger than VAS
recipients (P<0.0001).
bP for equal distribution among participants<0.0001. P for equal distribution between non-participants and participants¼0.06.
cP for equal distribution between non-participants and participants<0.0001. P for equal distribution between no-VAS recipients
and VAS recipients<0.0001.
dP for equal distribution among participants <0.0001. P for equal distribution among participants<0.0001. P for equal distribution
between no-VAS recipients and VAS recipients<0.0001.
eControlled for age, MUAC tended to be higher in VAS alone compared with VASþDTPþMV (P¼0.07). No-VAS recipients higher
MUAC than VAS recipients (P¼0.02).
308 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYon mortality of VAS given with vaccines. In the
present study, VAS with DTP was associated with
increased mortality when compared with VAS alone.
This contrasted with the effect of VAS with MV,
which if anything was associated with decreased
mortality.
The present study was observational. Participation
was voluntary and depended on the mother bringing
the child to a vaccination post, all children received
VAS unless they were in a VAS-at-birth trial and
eligible children were not randomized to a vaccine.
There are considerable differences between the base-
line characteristics of the different groups, especially
the small group of children missing both DTP and MV
seemed to be different. We have attempted to control
for known potential confounders, and it should be
noted that age is inherently controlled for in the Cox
models we used. Nonetheless, there could be con-
siderable residual confounding, and all comparisons
between participants and non-participants and
between vaccine recipients and non-vaccine-recipients
should be judged with caution. However, there are
several observations in the present study, which
suggest that our findings are not merely the result
of confounding.
First, it could be speculated that those who received
vaccines during the campaign had more non-
compliant mothers (who had not followed the
normal vaccination schedule) and therefore a higher
risk of dying. In spite of control for maternal
schooling and nutritional status, this could have
confounded our comparison of VAS with any DTP
vs VAS alone. However, this would not explain the
contrasting effects of VAS given with any DTP vs VAS
given with MV. Though the group missing DTP as
well as MV may have been even less compliant than
the group missing MV alone, we would not expect it
to fully explain the contrasting effects of VAS given
with DTPþMV vs VAS given with MV. Furthermore,
if a different a priori risk of dying in the different
treatment groups explained their different mortality,
the mortality ratios should be reduced importantly by
control for nutritional status. Since this did not
happen, the increased mortality in the VAS with
any DTP group does not merely seem to be due to
confounding, but may be related to treatment.
Second, we know from previous studies that
travelling or ill children are more likely to die,
18 and
in the present study, the non-participants who were
travelling or too ill to participate in the campaign had
high mortality. However, non-participants did not
have the expected higher mortality compared with
participants who received VAS with any DTP. On the
contrary, participants who received VAS with any
DTP had considerably higher mortality than non-
participants. This was not the case for participants
who had received VAS with MV. It could be argued
that it was only mothers who perceived their children
in need of treatment who participated in the NIDs.
We did not register illness among participants, but
mothers in Guinea-Bissau would normally not bring
ill children for vaccinations, as also reflected by the
fact that illness in the child was given as a reason for
non-participation. Furthermore, a higher proportion
of frail children among those coming for VAS and
vaccination would not explain why it was only
children receiving VAS with DTP who did not benefit
from the campaign.
As DTP is associated with increased mortality in
girls, and MV is associated with decreased mortality,
particularly in girls,
19–22 we would a priori expect to
find decreased mortality after MV compared with
DTP. However, in the present study, the difference in
mortality between MV and DTP recipients was far
larger than usually observed. Furthermore, among
the children who did not receive VAS because they
were in a VAS-at-birth trial, the MR (55/1000 pyrs)
after DTP alone was lower than the MR among
children who received VAS with DTP [140/1000 pyrs
(Table 3)], suggesting that VASþDTP may be
associated with higher mortality than DTP alone.
Hence, in the present study, we found several
indications that VAS given with DTP had negative
effects in contrast to VAS given with MV alone.
Table 3 Effect on mortality of receiving vitamin A supplementation with different types of vaccines (Guinea-Bissau
2003–04)
All Boys Girls
Deaths/pyrs
(MR)
a
MRR Deaths/pyrs
(MR)
a
MRR Deaths/pyrs
(MR)
a
MRR
VAS alone 12/282.4 (42) 1 (ref) 6/141.0 (43) 1 (ref) 6/141.5 (42) 1 (ref)
VASþany DTP 8/57.2 (140) 3.43 (1.36–8.61) 5/28.5 (175) 4.71 (1.37–16) 3/28.7 (105) 2.21 (0.52–9.44)
VASþMV 0/59.3 (N/A) 0 deaths 0/30.8 (N/A) 0 deaths 0/28.5 (N/A) 0 deaths
P for homogeneity
VASþanyDTP vs
VASþMV
b
0.0005 0.007 0.03
aMR¼deaths/1000 pyrs.
bTested using stratified log-rank test. All estimates and P-values are adjusted for age, suburb and maternal schooling. The overall
estimate was furthermore adjusted for sex.
VITAMIN A SUPPLEMENTATION AND VACCINES 309However, we cannot exclude residual confounding in
the comparisons of participants and non-participants
and between recipients of different vaccines.
Furthermore, the number of deaths was small, and
it could be argued that it was a chance finding. Based
on this study alone, no conclusions regarding the
potential interactions between VAS and vaccines can
be made. However, it should be noted that all
currently available data indicate that the combination
of VAS and DTP may be problematic, and we had a
priori formulated the hypothesis of a negative effect.
4
The WHO recommends VAS at vaccination contacts
after the age of 6 months. The first vaccine to be
received after 6 months of age would normally be
MV. However, many children come late for vaccina-
tions. In Guinea-Bissau, approximately one-third of
all children in the urban area and two-thirds in the
rural receive at least one DTP vaccine after 6 months
of age. Thus, in practice, there will be children coming
for MV, DTP or DTP plus MV for their first
vaccination contact after 6 months of age. Based
on the present evidence, the WHO VAS policy
may not be beneficial for children whose first
vaccination after 6 months is a DTP vaccine. Large,
randomized studies of the impact on survival of the
current WHO recommendation of providing VAS at all
vaccination contacts after 6 months of age seem
warranted.
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